Revista espanola de geriatria y gerontologia · 2025
Evaluating ferric carboxymaltose administration in elderly patients: Clinical outcomes, comparative characteristics in different care settings and cost analysis. A five year study.
СтатьяНаблюдательное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García-Calderón Díaz María Noemí, Medina Nieto Antonio, Ballesteros Arana Mateo, Manzanilla Meneses Valentina, Barriga Pineda Evelyn, García Matta Pedro, Castro Medina Gabriela, Tornero Torres Olga, Gómez Pavón Javier
Аннотация
BACKGROUND AND OBJECTIVE: Iron deficiency anemia is prevalent in the elderly, with ferric carboxymaltose increasingly used for intravenous iron supplementation. Evaluating its safety, efficacy, and cost implications in various care settings is essential. This study assesses the clinical outcomes, adverse reactions, and cost-effectiveness of administering ferric carboxymaltose to elderly patients across different care settings over five years.
METHODS: This retrospective observational cohort study included 198 elderly patients who received ferric carboxymaltose at a Geriatric Day Hospital from January 1, 2019, to December 31, 2023. Data on sociodemographic, clinical, and laboratory factors, along with adverse reaction records, were collected. Costs of administration at the Geriatric Day Hospital were compared with hypothetical costs if administered at home or in a nursing home by a Geriatric Home Hospitalization unit.
RESULTS: A total of 279 doses of ferric carboxymaltose were administered. Mean age of 87.3 years, 70% women. Primary indication for treatment was intestinal iron malabsorption (62.7%). Treatment was generally safe, no severe adverse reactions; mild adverse reactions occurred in 5.73% of doses, mainly involving arterial hypo- or hypertension. Patients in nursing homes exhibited higher functional dependence, frailty, and comorbidity compared to those living at home. Cost analysis showed potential savings of €39,353.80 with administration by the Geriatric Home Hospitalization unit, attributed to lower operational and personnel costs.
CONCLUSIONS: Ferric carboxymaltose is safe and effective for elderly patients, including those with high frailty and comorbidity. Administering this treatment in home or nursing home settings is cost-effective, potentially enhancing accessibility and reducing overall healthcare costs.
METHODS: This retrospective observational cohort study included 198 elderly patients who received ferric carboxymaltose at a Geriatric Day Hospital from January 1, 2019, to December 31, 2023. Data on sociodemographic, clinical, and laboratory factors, along with adverse reaction records, were collected. Costs of administration at the Geriatric Day Hospital were compared with hypothetical costs if administered at home or in a nursing home by a Geriatric Home Hospitalization unit.
RESULTS: A total of 279 doses of ferric carboxymaltose were administered. Mean age of 87.3 years, 70% women. Primary indication for treatment was intestinal iron malabsorption (62.7%). Treatment was generally safe, no severe adverse reactions; mild adverse reactions occurred in 5.73% of doses, mainly involving arterial hypo- or hypertension. Patients in nursing homes exhibited higher functional dependence, frailty, and comorbidity compared to those living at home. Cost analysis showed potential savings of €39,353.80 with administration by the Geriatric Home Hospitalization unit, attributed to lower operational and personnel costs.
CONCLUSIONS: Ferric carboxymaltose is safe and effective for elderly patients, including those with high frailty and comorbidity. Administering this treatment in home or nursing home settings is cost-effective, potentially enhancing accessibility and reducing overall healthcare costs.